These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 23756162

  • 1. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
    Pezeshki AM, Azar GA, Mourad W, Routy JP, Boulassel MR, Denzin LK, Thibodeau J.
    Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
    [Abstract] [Full Text] [Related]

  • 2. Selective binding of bacterial toxins to major histocompatibility complex class II-expressing cells is controlled by invariant chain and HLA-DM.
    Lavoie PM, Thibodeau J, Cloutier I, Busch R, Sékaly RP.
    Proc Natl Acad Sci U S A; 1997 Jun 24; 94(13):6892-7. PubMed ID: 9192662
    [Abstract] [Full Text] [Related]

  • 3. Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules.
    Soos JM, Russell JK, Jarpe MA, Pontzer CH, Johnson HM.
    Biochem Biophys Res Commun; 1993 Mar 31; 191(3):1211-7. PubMed ID: 8466498
    [Abstract] [Full Text] [Related]

  • 4. Quantitative defect in staphylococcal enterotoxin A binding and presentation by HLA-DM-deficient T2.Ak cells corrected by transfection of HLA-DM genes.
    Albert LJ, Denzin LK, Ghumman B, Bangia N, Cresswell P, Watts TH.
    Cell Immunol; 1998 Jan 10; 183(1):42-51. PubMed ID: 9578718
    [Abstract] [Full Text] [Related]

  • 5. Binding of toxic shock syndrome toxin-1 to murine major histocompatibility complex class II molecules.
    Scholl PR, Sekaly RP, Diez A, Glimcher LH, Geha RS.
    Eur J Immunol; 1990 Sep 10; 20(9):1911-6. PubMed ID: 2209697
    [Abstract] [Full Text] [Related]

  • 6. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
    von Bonin A, Ehrlich S, Malcherek G, Fleischer B.
    Eur J Immunol; 1995 Oct 10; 25(10):2894-8. PubMed ID: 7589089
    [Abstract] [Full Text] [Related]

  • 7. Carboxy-terminal residues of major histocompatibility complex class II-associated peptides control the presentation of the bacterial superantigen toxic shock syndrome toxin-1 to T cells.
    Wen R, Broussard DR, Surman S, Hogg TL, Blackman MA, Woodland DL.
    Eur J Immunol; 1997 Mar 10; 27(3):772-81. PubMed ID: 9079821
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification of MHC class II-associated peptides that promote the presentation of toxic shock syndrome toxin-1 to T cells.
    Hogan RJ, VanBeek J, Broussard DR, Surman SL, Woodland DL.
    J Immunol; 2001 Jun 01; 166(11):6514-22. PubMed ID: 11359802
    [Abstract] [Full Text] [Related]

  • 11. Structural basis for differential binding of staphylococcal enterotoxin A and toxic shock syndrome toxin 1 to class II major histocompatibility molecules.
    Pontzer CH, Russell JK, Johnson HM.
    Proc Natl Acad Sci U S A; 1991 Jan 01; 88(1):125-8. PubMed ID: 1986357
    [Abstract] [Full Text] [Related]

  • 12. Dissection of the function of HLA class II and costimulation in B cell-mediated and toxic shock syndrome toxin-1-induced T cell proliferation.
    Dennig D, O'Reilly RJ.
    J Immunol; 1993 Jun 15; 150(12):5231-40. PubMed ID: 7685791
    [Abstract] [Full Text] [Related]

  • 13. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens.
    Zhu X, Bavari S, Ulrich R, Sadegh-Nasseri S, Ferrone S, McHugh L, Mage M.
    Eur J Immunol; 1997 Aug 15; 27(8):1933-41. PubMed ID: 9295029
    [Abstract] [Full Text] [Related]

  • 14. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB, Arndt SO, Hämmerling GJ, Kropshofer H.
    Semin Immunol; 1999 Dec 15; 11(6):391-403. PubMed ID: 10625593
    [Abstract] [Full Text] [Related]

  • 15. Identification from a phage display library of peptides that bind to toxic shock syndrome toxin-1 and that inhibit its binding to major histocompatibility complex (MHC) class II molecules.
    Sato A, Ida N, Fukuyama M, Miwa K, Kazami J, Nakamura H.
    Biochemistry; 1996 Aug 13; 35(32):10441-7. PubMed ID: 8756700
    [Abstract] [Full Text] [Related]

  • 16. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
    Vogt AB, Stern LJ, Amshoff C, Dobberstein B, Hämmerling GJ, Kropshofer H.
    J Immunol; 1995 Nov 15; 155(10):4757-65. PubMed ID: 7594477
    [Abstract] [Full Text] [Related]

  • 17. Toxic shock syndrome toxin 1 binds to major histocompatibility complex class II molecules.
    Scholl P, Diez A, Mourad W, Parsonnet J, Geha RS, Chatila T.
    Proc Natl Acad Sci U S A; 1989 Jun 15; 86(11):4210-4. PubMed ID: 2542966
    [Abstract] [Full Text] [Related]

  • 18. Detection of aberrant association of DM with MHC class II subunits in the absence of invariant chain.
    Neumann J, König A, Koch N.
    Int Immunol; 2007 Jan 15; 19(1):31-9. PubMed ID: 17105964
    [Abstract] [Full Text] [Related]

  • 19. H2-O inhibits presentation of bacterial superantigens, but not endogenous self antigens.
    Qi L, Ostrand-Rosenberg S.
    J Immunol; 2001 Aug 01; 167(3):1371-8. PubMed ID: 11466355
    [Abstract] [Full Text] [Related]

  • 20. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality.
    Kum WW, Laupland KB, Chow AW.
    Can J Microbiol; 2000 Feb 01; 46(2):171-9. PubMed ID: 10721486
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.